AbbVie Inc. (ABBV)
| Previous close | 106.10 |
| Open | 106.39 |
| Bid | 107.42 x 1300 |
| Ask | 107.50 x 800 |
| Day's range | 106.05 - 107.72 |
| 52-week range | 78.66 - 113.41 |
| Volume | 5,903,250 |
| Avg. volume | 7,442,741 |
| Market cap | 189.79B |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | 39.54 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 5.20 (4.84%) |
| Ex-dividend date | 14 Apr 2021 |
| 1y target est | N/A |
- PR Newswire
AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA
AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for SKYRIZI® (risankizumab-rzaa, 150 mg) to the U.S. Food and Drug Administration (FDA) and for SKYRIZI® (risankizumab, 150 mg) to the European Medicines Agency (EMA) for the treatment of adults with active psoriatic arthritis.1 The submissions were supported by two pivotal Phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2, which evaluated SKYRIZI in adults with active psoriatic arthritis including those who had responded inadequately or were intolerant to biologic therapy and/or non-biologic disease-modifying anti-rheumatic drugs (DMARDs).1
- PR Newswire
AbbVie to Present Data Across its Robust Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting
AbbVie (NYSE: ABBV) today announced new data from its expansive neuroscience portfolio will be presented at the 2021 American Academy of Neurology (AAN) Annual Meeting, to be held virtually from April 17-22. A total of 33 abstracts, including one podium presentation during the Clinical Trials Plenary Session and three oral presentations, will be shared from a broad range of studies across the spectrum of migraine, advanced Parkinson's disease and spasticity.
- PR Newswire
AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis
AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adults and adolescents with moderate to severe atopic dermatitis. The Prescription Drug User Fee Act (PDUFA) action date has been extended three months to early Q3 2021.
